Tecsys Placed as a Challenger in 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems
Recognized for completeness of vision and ability to execute.
MONTREAL, May 7, 2025 /PRNewswire/ -- Tecsys Inc. (TSX: TCS), a leading and innovative provider of solutions in the warehouse management systems market, today announced that it has been positioned by Gartner as a Challenger in the Magic Quadrant for Warehouse Management Systems for its vision and execution.1 This marks the 14th time Tecsys has been recognized in this report.2 The evaluation was based on specific criteria that analyzed the company's overall Completeness of Vision and Ability to Execute.
TECSYS (PRNewsfoto/TECSYS)
Tecsys' Elite™ WMS delivers supply chain clarity through real-time visibility, actionable insights and robust warehouse control, helping organizations manage high-complexity environments and streamline distribution operations. Purpose-built for mission critical supply chains in healthcare, third-party logistics and complex distribution, Elite™ enables teams to optimize throughput, reduce operating costs and elevate service levels.
"We're proud of our continued evolution in the WMS space," said Peter Brereton, president and CEO of Tecsys. "We see our placement reflecting the strength of our customer partnerships and the operational impact we deliver in complex, high-value supply chains. Our perspective is that Elite™ WMS has become a cornerstone for organizations looking to drive meaningful improvements in efficiency and service."
Magic Quadrant reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables you to get the most from market analysis in alignment with your unique business and technology needs.
View a complimentary copy of the Magic Quadrant report to learn more about Tecsys' strengths and cautions, among other provider offerings, at http://www.tecsys.com/gartner-wms-mq.
Additional resources
View a complimentary copy of the Magic Quadrant report: http://www.tecsys.com/gartner-wms-mq
Explore Tecsys solutions: https://www.tecsys.com/elite-solutions/warehouse-management
1 Source: Gartner, Magic Quadrant for Warehouse Management Systems, By Simon Tunstall, Dwight Klappich, Rishabh Narang, Federica Stufano, May 1, 2025.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
36 minutes ago
- Business Wire
Hydrogen lift-off: Intelligent Energy secures £17m programme to scale its UK-developed aviation fuel cell tech
LOUGHBOROUGH, England--(BUSINESS WIRE)-- Intelligent Energy (IE), one of the UK's leading hydrogen fuel cell manufacturers, has secured a £17 million programme to fast-track development of a new zero-emission hydrogen fuel cell system that could be powering commercial aircraft within the decade. The award is from the ATI Programme, a partnership between the Aerospace Technology Institute (ATI), the Department for Business & Trade and Innovate UK. It will support Project HEIGHTS – a three-year drive to develop IE's current 300kW modular aviation fuel cell platform for use in next-generation aircraft. Initial applications include Electric Vertical Take-off and Landing (eVTOL) aircraft and short-range commuter planes. IE's new fuel cell system – IE-FLIGHT™ 300 – is expected to enter early service in Part 23 aircraft (with up to 19 seats) by the end of the decade, with scale-up plans targeting larger (Part 25) regional aircraft in the 2030s. The project addresses the key challenge with traditional fuel cell systems – how to keep the fuel cells at the correct operating temperature without introducing significant aircraft drag from cooling systems. In aviation particularly, minimising the heat exchanger size is critical to reduce mass and drag, and to optimise overall efficiency. IE's patented direct water-injection technology uses air-cooled condensers with a smaller frontal area than conventional liquid glycol radiators. In Project HEIGHTS, IE will further develop this novel cooling method to achieve a significant reduction in heat exchanger size. The investment comes as aviation faces rising pressure to cut emissions. Batteries remain constrained by weight and range, while hydrogen-electric propulsion is gaining traction as a cleaner, scalable alternative. The project marks a major step forward for Intelligent Energy, and its fuel cell technology offers significant environmental and economic benefits to the aviation sector. A switch to fuel cell systems across eVTOL, sub-regional and regional aircraft, as well as Auxiliary Power Units (APUs) on larger aircraft, could reduce CO₂ emissions by up to 25.6 million tonnes per year. IE estimates the total market value – encompassing both sales and servicing revenue – is £19.6 billion, and scaling up production could create as many as 1,600 new jobs. 'This programme is about getting hydrogen-powered aircraft in the air, and into service at scale, as quickly as possible,' David Woolhouse, Intelligent Energy CEO, said. 'We firmly believe that hydrogen will be the primary energy source for flight, initially for smaller aircraft but in the longer term for everything that flies. At Intelligent Energy, we have the IP built on 24 years' experience to give us confidence that we can be the technical leader in this sector. This project supports us in making our modular system even smaller, lighter and more scalable.' HEIGHTS – which stands for Hydrogen Efficient fuel cell Integrated in a High Temperature System – builds on Intelligent Energy's previous involvement in H2GEAR, a separate ATI-backed programme led by GKN Aerospace. It leverages the company's extensive aviation experience, including powering the world's first manned fuel cell flight with Boeing in 2008. The funding announcement is a significant milestone for IE's aviation division. In February, the company was named as a strategic partner in the UK Civil Aviation Authority's Hydrogen Challenge programme. IE is also expanding its UK operations. In addition to its manufacturing base in Loughborough, the company is enhancing its test and validation capabilities with a new £7.1 million fuel cell test centre opening this summer in Northamptonshire. 'We are expanding at pace because the UK has a once-in-a-generation opportunity to consolidate its global lead in hydrogen aviation and build a strong domestic manufacturing capability,' said Woolhouse. 'The hydrogen economy for aviation will be a major industrial sector, and this support from ATI helps to keep our technology here in the UK. For investors focused on green technology and mobility applications, HEIGHTS reinforces our unique value – clear IP differentiation, proximity to market, and a regulatory tailwind that's only getting stronger.' Jacqueline Castle, Chief Technology Officer at the Aerospace Technology Institute said: 'Hydrogen as a fuel source is an essential part of the ATI's technology roadmaps for future power and propulsion systems. We are delighted to be supporting Intelligent Energy's HEIGHTS programme, which builds upon its prior expertise in fuel cell development to encompass novel means of addressing thermal management challenges associated with aircraft integration. 'The ATI's FlyZero project identified the need for high-temperature fuel cell systems and world-class expertise on thermal management within the UK. This project brings the two together to develop what we expect to be a compelling, power dense solution for zero-carbon flight.' ENDS Images and video footage Download Images About Intelligent Energy Limited Intelligent Energy is a leader in the development and manufacture of cutting-edge hydrogen fuel cells that overcome the limitations of conventional battery-powered systems. Established in 2001, the privately-owned company, which has 600 patents in place, has been innovating for more than two decades in the automotive, aerospace, power generation, telecoms, materials handling and unmanned aerial vehicle (UAV) sectors. Headquartered in Loughborough UK, Intelligent Energy has a global reach, with activities spanning key markets in the UK, US, China, South Korea, and Japan. Discover more at Intelligent Energy
Business Wire
37 minutes ago
- Business Wire
SunRock Biopharma and Escugen Forge Alliance to Develop First-in-Class CCR9-Targeted ADC
SANTIAGO DE COMPOSTELA, Spain & SHANGHAI--(BUSINESS WIRE)--SunRock Biopharma and Escugen have joined forces in a strategic partnership to co-develop SRB123, a First-in-Class antibody-drug conjugate (ADC) targeting C-C motif chemokine receptor 9 (CCR9), a tumor-associated antigen overexpressed in multiple solid tumors, including pancreatic, ovarian and lung cancer. SunRock Biopharma and Escugen have entered a strategic partnership to co-develop SRB123, a first-in-class antibody-drug conjugate targeting CCR9, a tumor-associated antigen overexpressed in pancreatic, ovarian and lung cancers Share The collaboration combines SunRock's proprietary SRB1 antibody, selected for its high binding affinity and efficient tumor cell internalization, with Escugen's EZWi-Fit™ linker-payload platform, a next-generation ADC technology optimized for the linker stability and selective tumor release of the potent payload. The result is a highly differentiated therapeutic candidate designed exclusively for solid tumors with high CCR9 expression and internalization rates. Under the agreement, both companies will share development responsibilities, file joint patents, and hold reciprocal licensing option rights. The primary goal is to generate robust preclinical proof-of-concept data to support early clinical entry in the near term. 'Combining our deep antibody engineering expertise with Escugen's innovative conjugation platform enables us to deliver a precision oncology candidate with First-in-Class potential,' said Dr. Laureano Simón, CEO of SunRock. 'CCR9 remains an underexploited but clinically validated target. This program addresses real unmet needs in aggressive tumors with poor prognosis.' Dr. Qing Zhou, Co-Founder and CEO of Escugen, stated, 'This strategic collaboration with SunRock Biopharma aligns with our vision of developing First-in-Class precision oncology candidates through technological innovation. It further highlights the unique advantages of our EZWi-Fit™ platform technology in next-generation ADC development. The platform's strong anti-tumor activity and favorable tolerability provide a solid foundation for targeting high CCR9-expressing solid tumors. We are confident that combining our expertise will accelerate SRB123's progress and bring new hope to patients.' CCR9 has been associated with metastatic potential and chemoresistance, particularly in pancreatic and ovarian cancers. SRB1, the unconjugated antibody from SunRock, has already demonstrated strong preclinical efficacy in these models. The ADC format (SRB123) leverages this targeting while enhancing tumor cell killing via Escugen's payload delivery system. The partnership will be showcased during the BIO International Convention 2025, where both companies will engage with potential development and commercialization partners. About SunRock Biopharma SunRock Biopharma is a biotech company focused on developing next-generation antibody-based therapies targeting unmet medical needs in oncology and immunology. Operating under an open innovation model, SunRock combines cutting-edge academic science, advanced technology platforms, and a selective business approach to generate highly differentiated, licensable assets. Its portfolio includes optimized monoclonal antibodies, next-generation ADCs, and radioconjugates, with validated targets such as CCR9 and HER3. SunRock follows an early-stage out-licensing strategy, designed to maximize risk-adjusted returns, and maintains active collaborations with leading pharma and biotech partners worldwide. About Escugen Escugen is a clinical-stage biotechnology company located in Shanghai, China, focusing on the development of innovative ADC drugs. Currently, Escugen's lead Trop-2 ADC pipeline, ESG401, has entered Phase III clinical trials. Escugen's next-generation linker-payload technology platform, EZWi-Fit®, offers significant competitive advantages in terms of safety, efficacy, anti-multiple drug resistance, and pharmacokinetic characteristics. Leveraging this platform technology, Escugen is rapidly expanding its ADC pipeline targeting new or validated target. The first ADC product baring the EZWi-Fit® technology has successfully launched its FIH clinical campaign. In addition, Escugen has licensed this platform technology to several domestic and international biotechnology companies to empower their innovative ADC projects.
Hamilton Spectator
an hour ago
- Hamilton Spectator
Clothing retailer Groupe Dynamite reports Q1 profit and revenue up from year ago
MONTREAL - Groupe Dynamite Inc. reported a first-quarter profit of $27.3 million, up from $23.9 million a year ago as its revenue rose 20 per cent. The clothing retailer, which operates under the Garage and Dynamite banners, says the profit amounted to 24 cents per diluted share for the quarter ended May 3. The result was up from 22 cents per diluted share in the same quarter last year. On an adjusted basis, Groupe Dynamite says it earned 25 cents per diluted share in its latest quarter, up from an adjusted profit of 23 cents per diluted share a year ago. Revenue totalled $226.7 million, up from $188.9 million, while comparable store sales rose 13.0 per cent. In its outlook, Groupe Dynamite says it now expects comparable store sales growth for its full year between 7.5 per cent and 9.0 per cent, up from earlier guidance for between 5.0 per cent and 6.5 per cent. This report by The Canadian Press was first published June 17, 2025. Companies in this story: (TSX:GRGD)
